5-azacytidine-induced protein 2 (AZI2)

5-azacytidine-induced protein 2 (AZI2, or NAP1) is an adapter protein critical for regulating the activation and recruitment of TBK1 kinase in the context of TNF receptor signaling complexes (TNF-RSC) and antiviral pathways. AZI2 is recruited to signaling complexes via NEMO and the deubiquitinase A20, following distinct kinetics from its related adapter TANK. Its main function is to sustain TBK1 activation, thereby suppressing RIPK1-mediated cell death and supporting NF-kappa-B-dependent transcriptional responses. AZI2 also participates in selective autophagy responses and IFN-beta induction. Loss of AZI2, especially combined with loss of TANK, leads to severe multi-organ inflammation, increased cell death, immune dysregulation, and early mortality in model organisms. AZI2 is considered a key therapeutic target in immune homeostasis and may be relevant in cancer, inflammation, and viral infection settings. If additional, more structural molecular classifications (e.g., with high-resolution structure or complex formation analyses) become available, those would further specify the protein’s functional domains.

Other names

NAP1TBKBP2Nak-associated protein 1FLJ21939AZ2NF-kappa-B-activating kinase-associated protein 1TILP5-azacytidine induced gene 2

Drugs targeting this pathway would likely inhibit or modulate adaptor-mediated TBK1 activation, suppressing downstream NF-kappa-B signaling or interferon induction.